Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Kamada Ltd. (KMDA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.5000-0.0500 (-1.10%)
At close: 04:00PM EDT
4.5600 +0.06 (+1.33%)
After hours: 05:18PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.5500
Open4.5300
Bid4.4000 x 1000
Ask5.3800 x 1000
Day's Range4.5000 - 4.5300
52 Week Range4.4200 - 6.9600
Volume3,935
Avg. Volume17,255
Market Cap201.602M
Beta (5Y Monthly)0.23
PE Ratio (TTM)N/A
EPS (TTM)-0.1500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KMDA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kamada Ltd.
    Analyst Report: Incyte Corp.Founded in 1991 and based in Wilmington, Delaware, Incyte is a drug discovery and development company. The company has several small-molecule compounds in clinical trials, while its primary revenue-generating products include Jakafi, Iclusig, Pemazyre, and Olumiant. Jakafi treats polycythemia vera (PV), a type of blood cancer; myelofibrosis (MF), a rare bone marrow disorder; and steroid-refractory acute graft-versus-host-disease (GVHD), while Iclusig treats leukemia, Pemazyre treats bile duct cancer, and Olumiant treats rheumatoid arthritis. The company also recently launched Tabrecta, for non-small-cell lung cancer, and has several active Phase 2 and 3 programs in oncology.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
Advertisement
Advertisement